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Abstract: 
The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is 
essential for viral entry and represents a major target for humoral responses 
following infection. Previously, a phase-2 placebo-controlled clinical trial conducted 
in solid organ transplant candidates demonstrated that vaccination with gB plus 
MF59 adjuvant significantly increased gB ELISA antibody levels whose titer 
correlated directly with protection against post-transplant viremia. The aim of the 
current study was to investigate in more detail this protective humoral response in 
vaccinated seropositive transplant recipients. We focussed on four key antigenic 
domains (AD) of gB; AD1, AD2, AD4 and AD5 measuring antibody levels in patient 
sera and correlating these with post-transplant HCMV viremia. Vaccination of 
seropositive patients significantly boosted pre-existing antibody levels against the 
immunodominant region AD1 as well as against AD2, AD4 and AD5. A decreased 
incidence of viremia correlated with higher antibody titers against AD2 but not with 
antibody titers against the other three ADs. Overall, these data support the 
hypothesis that antibodies against AD2 are a major component of the immune 
protection of seropositives seen following vaccination with gB/MF59 vaccine and 
identify a correlate of protective immunity in allograft patients.  
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Introduction: 
Human cytomegalovirus (HCMV) is a ubiquitous human pathogen [1]. Primary 
infection is normally asymptomatic in healthy individuals, likely reflecting control of 
virus replication by the immune system. However, HCMV can be a major cause of 
morbidity following infection of immunocompromized individuals such as solid organ 
transplant (SOT) patients, hematopoietic stem cell transplant recipients [2-5], fetuses 
infected in utero [6, 7] and late stage AIDS patients [8, 9]. The socioeconomic and 
clinical burden of CMV infection led the Institute of Medicine to designate 
development of a HCMV vaccine as the highest priority [10]. The first attempts to 
vaccinate against HCMV were made with live attenuated Towne and AD169 strains 
[11, 12] followed by subunit and vectored vaccines reviewed elsewhere [13, 14], but, 
a HCMV vaccine is not yet licensed for clinical use.  
The glycoprotein B (gB) protein is highly conserved across the herpesvirus family 
and is essential for viral entry [15-17]. Neutralizing and function blocking antibodies 
(i.e. antibodies that bind to an antigen and inhibit its normal function without 
necessarily destroying the pathogen) targeting gB effectively inhibit HCMV infection 
in vitro. Early studies speculated that most (40-70%) of the serum-neutralizing 
activity against HCMV in vivo is directed towards gB [18]. These estimates were 
based on neutralization of fibroblast infection largely with laboratory strains whereas 
additional complexes are now known to perform cell type specific functions in entry 
(most notably the pentameric complex in non-fibroblast cells) [19]. However, the role 
of gB in entry into all cell types retains this protein as an attractive target for 
vaccination.  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy102/4924673
by Periodicals Section , London Metropolitan University user
on 12 March 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Support for gB as an attractive vaccine component comes from studies with animal 
models demonstrating that a recombinant gB-vaccine decreased the rate of virus 
transmission in pregnant guinea pigs and mortality amongst new-born pups [20]. In 
humans, gB vaccine with MF59 adjuvant (gB/MF59) proved to be safe and 
immunogenic [21-23], reducing primary infection in adult women by approximately 
50% [24], by 42% in adolescent girls and partially controlling viremia in SOT 
recipients [25] [26].  
Although all 3 phase-2 clinical trials of gB/MF59 provide evidence of a protective 
effect the exact correlates of protection remain unclear [25-27]. In the SOT patients 
the duration of viremia was inversely correlated with the anti-gB antibody titer 
suggesting that humoral responses may be protective [25]. The humoral response 
against gB is polyclonal with 5 major antigenic domains (ADs) identified [28]. The 
first highly conserved neutralizing epitope was identified on gp55 of gB using 
monoclonal antibodies [29]. A defined stretch of amino acids (608-625 aa) was a 
component of the larger AD1 region which consists of approximately 80aa between 
positions 560 and 640 of gB (gp58) in the AD169 strain [30]. Subsequent homology 
studies between Towne and AD169 strains revealed AD2 containing two binding 
sites: site I, located between 68-77aa, is conserved amongst strains and antibodies 
that bound to this site were neutralizing; site II, located between 50-54aa, is 
unconserved between strains and bound antibodies were incapable of neutralizing 
the virus [31]. An additional linear epitope, AD3, was mapped to a sequence in the 
intraluminal part of the gB molecule (between 798 to 805aa) suggesting that this 
region may not be exposed to neutralizing antibody responses. Most recently, an 
analysis of the repertoire of gB-specific memory B cells identified two structural 
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antibody domains targeted by antibodies with neutralizing activity. These were 
defined as domain I (AD5)- located between 133–343 aa- and domain II (AD4)- a 
discontinuous domain mapped to 121–132 aa and 344–438aa [28]. In summary, it is 
evident that AD1 is a major target of humoral response since nearly 100% of sera 
from HCMV healthy seropositive donors have antibodies that bind to this antigenic 
domain [32, 33]. However, because AD1 induces a mixture of neutralizing and non-
neutralizing specificities, it was initially suggested that antibodies directed against 
other domains, such as AD2, may confer better protection against HCMV infection 
[34]. This possibility requires further evaluation, especially now that AD4 and AD5 
have been identified. 
In this study we characterized the antibody repertoire against major antigenic 
domains of gB following natural infection and vaccination with gB/MF59 in the sera 
from patients who were naturally seropositive prior to vaccination. We report that 
vaccination boosted pre-existing responses but displayed a variable capacity to 
induce de novo responses against these ADs. Importantly, we provide evidence that 
responses against the AD2 domain directly correlate with better outcomes post-
transplant. Additionally, we provide evidence to suggest AD1 responses – which 
have been hypothesised to reduce the effectiveness of humoral immunity against 
HCMV – are not detrimental in this transplant patient cohort. More generally, the 
data illustrate the complexity of studying the immune response to identify correlates 
of protection to prevent HCMV viremia and disease. 
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Results 
Vaccination boosts pre-existing immune responses against epitopes of gB but 
only induces detectable de novo responses against some epitopes. 
To investigate serological responses we utilized ELISA assays against 4 key 
antigenic domains of gB: AD1, 2, 4 & 5 (Figs.1-4). Specific antibody responses were 
measured at five different time points (visits 1-5): day of vaccine/placebo 
administration (month 0- visit 1); day of administration of the second (month 1- visit 
2) and third dose (month 6; visit 4), and 2 (visit 3) and 7 months post vaccination 
(visit 5); (summarised in Table S1). 
To establish the background values for each antigenic domain we utilized sera from 
seronegative SOT patients collected at the time of their vaccine or placebo 
administration. We used the highest values detected in those seronegative 
individuals to establish cut-off points.  
The data show that nearly all HCMV seropositive individuals possess detectable 
antibodies against AD1 (Fig. 1A & B). Vaccination increased pre-existing antibody 
levels against AD1 in nearly all individuals (Fig. 1A & C). This boost was observed by 
dose 1 and subsequently sustained at increased levels up to the time of 
transplantation.  
Similar results were observed with AD4 (Fig. 2A & B). In seropositive patients with 
low-level baseline AD4 antibody responses we observed increased anti-AD4 
antibody levels post vaccination in some, but not all, individuals (Fig. 2A & C). 
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Sera from nearly all patients contained antibodies recognising AD5 (Fig. 3A & B). 
Vaccination increased pre-existing antibody levels against AD5 in the majority of 
patients (Fig. 3A & C). In the few patients with AD5 levels below the cut-off value (by 
ELISA) prior to vaccination we saw evidence that vaccination promoted de novo 
responses in some of these patients also.  
Approximately 50% of patients had levels of anti-AD2 antibodies above the 
background cut-off value prior to vaccination (Fig. 4 A and B). Administration of the 
first dose of gB/MF59 was sufficient to boost pre-existing antibody levels against 
AD2 in most HCMV seropositive SOT patients (Fig. 4 A and C). When the analysis 
was restricted to those with the levels of AD2 antibodies above the background cut-
off at baseline, it became clear that this boost was statistically significant, Fig. 4 D).  
Higher AD2 antibody levels correlate with lower incidence of viremia post 
transplantation. 
We next investigated the correlation between antibody levels against specific ADs 
and outcome post transplantation (Fig. 5). Despite clear evidence of a boost in 
responses to AD1, AD4 and AD5 (Figs. 1-3), there was no statistically significant 
correlation with the occurrence of viremia among the patients who underwent 
transplantation (Fig. 5A, C, D). However, we note that, in the case of AD4, a non-
significant trend was evident whereby patients who had higher levels of AD4 specific 
antibody responses were less likely to develop viremia (Fig. 5C). 
In contrast it was clear that the AD2 antibody level was significantly lower in the 
patients who developed viremia following transplant consistent with the hypothesis 
that antibodies against AD2 are protective (Fig. 5B). This protection was restricted to 
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patients with AD2 responses prior to vaccination since vaccination itself did not 
induce detectable AD2 responses de novo (Fig. 4). 
The correlation with protection observed with AD2 is not affected by AD1 
responses.  
We next asked whether these data could test for interactions between the antibody 
responses. Underpinning this approach is a prior hypothesis that AD1 responses 
may negatively impact on AD2 responses [35]. Theoretically, there are three 
possible relationships between the AD1 and AD2 antibody levels in vaccinated 
seropositive SOT recipients and their effect on outcome: I) competition (promoting 
viremia); II) additive effect (promoting protection); III) no direct interaction (Fig. 6A).  
To address this, we performed a two-component analysis where patient sera were 
stratified for outcome (viremia versus no viremia) and then both AD1 and AD2 
responses plotted. The resulting graph demonstrates no correlation between the 
AD2 and AD1 levels in seropositive SOT recipients post vaccination that segregated 
with viremia (Fig. 6B). However, attempts to explore this further using multivariable 
statistical analysis were not possible because the clinical trial population size 
provided insufficient data points for more complex analyses (results not shown).  
Discussion 
This work illustrates the complexity of studying immune responses to HCMV in 
seropositives. For example, HCMV establishes latency from which it periodically 
reactivates which could alter the pattern of immunological responses seen at any 
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time of analysis irrespective of any external vaccine administration. To control for 
this, we examined not only vaccinated patients but also seropositive recipients of 
placebo at the same time points. This allowed us to follow natural changes in the 
composition of the humoral immune response in seropositive transplant candidates 
who experienced a virus challenge at the time of transplantation. Here we aimed to 
provide more insight into the protective nature and fine specificity of the humoral 
responses against gB. To be classified as a correlate of protection following 
vaccination, any immunological responses would need to be induced or boosted by 
the vaccine and to correlate with protection against post-transplant viremia [25]. 
A major observation in this study was boosting of pre-existing responses to all four 
antigenic domains by gB/MF59. However, only antibody titers against AD2 correlated 
with protection against viremia. This illustrates that, for vaccine development, 
demonstrating immunogenicity is not sufficient and requires supplementation with 
studies of protection in human challenge models, such as that employed here. We 
demonstrated that AD2 antibody levels displayed the strongest correlation with 
protection in our seropositive patient cohort. However, the vaccine was not observed 
to induce de novo AD2 responses, but boosted pre-existing responses. Previous 
studies have shown approximately 50% of infected individuals possess antibodies 
against site I of AD2 following natural infection [31-33, 36] and the data we present 
here are consistent with this. Recent structural and immunochemical analyses 
suggest that the anti-AD2 specific immunological responses may be created though 
a cascade of rare and very specific immunoglobulin gene re-arrangement events [34, 
37]. Possibly, therefore, the variable response towards this epitope following both 
natural infection and vaccination with gB/MF59 and Towne based vaccines is a 
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consequence of the low probability of developing antibodies that require 
recombination of one of two well-conserved human germline V elements (IGHV3-30 
and IGKV3-11), and IGHJ4 and the possibility of antigen competition through the 
simpler production of AD1 antibodies [35]. Antibodies against AD2 are also 
characterized by specific substitutions at certain positions that seem to be crucial for 
high affinity binding to this epitope [34, 38-40]. Although only a proportion of infected 
individuals develop these AD2 antibodies, they may contribute an important 
neutralizing activity for controlling infection [36, 40-42]. Thus an immunogen that can 
enhance or generate de novo responses against AD-2 may be a good candidate for 
a new HCMV vaccine. It is important to re-iterate that our data suggest that, whilst 
pre-existing AD2 responses established at the time of primary infection or 
reactivation of the virus from latency can be enhanced, the gB/MF59 vaccine does 
not induce detectable AD2 responses in those lacking them at baseline. However, 
the study did reveal a marked increase in AD2 levels in one recipient of placebo. We 
hypothesise that this might be a response to reactivation of latent virus or even a re-
infection event in this patient prior to transplant illustrating how responses may 
develop over time. Although these data support a role for AD2 antibodies in the 
control of HCMV infection, other components of the humoral response could be 
important as well, including AD4 that deserves further investigation. In vitro studies 
show that AD4 specific antibodies have a high neutralizing capacity at the post-
adsorption step [28]. Indeed, antibodies that bind to the AD4 corresponding 
sequence on HSV-gB inhibit the interaction of gB with gH/gL complex with a 
downstream effect on viral fusion [43]. Antibodies that impeded this aspect of viral 
entry could potentially impact on viral infection. Although the AD4 association did not 
reach statistical significance, this could be due to the number of patients available to 
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us. Serological analysis of this vaccine cohort revealed that the AD1 and AD5 
antibody levels did not correlate with protection. The humoral response to natural 
infection against the immunodominant region AD1 has variable neutralizing capacity 
[44, 45]. Competition between non-neutralizing and neutralizing antibodies against 
AD1 was reported [18, 29, 45] suggesting that AD1 antibody binding may even 
provide an immune-evasive mechanism by preventing the binding of other 
neutralizing antibodies to cell free virus [44]. It is tempting to speculate whether AD1 
should be removed from HCMV subunit vaccines. If the elimination of AD1 improved 
antibody responses against protective epitopes this would support such a 
modification (as has been proposed for AD2) although we could find no evidence in 
our cohort to support this hypothesis. Additionally, we cannot rule out that AD1 
provides key structural information ensuring the better presentation of ‘good’ 
epitopes. Indeed, attempts to engineer gB without AD1 have proven difficult as AD1 
is necessary for oligomerization and the structural integrity of gB [46]. This lack of 
structural information may explain a pre-clinical study that demonstrated a peptide-
based vaccine specific to the HCMV gB AD2 region elicited only poor neutralizing 
antibody responses [47]. However, we also emphasise that we have previously 
reported [25] that protection given by this vaccine did not correlate with neutralizing 
activity. This is not to disregard neutralisation as a strategy since preclinical studies 
with monoclonal anti-AD2 antibody (TRL345) have shown promising results 
supporting further investigation as a candidate for clinical evaluation [48].  
Although our analyses of the AD5 humoral response did not reveal a protective 
correlation it did reveal some interesting information regarding the response to this 
antigen. [28] [49]. First reports of AD5 immunogenicity suggested approximately 50% 
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of seropositive individuals developed AD5 antibodies [28]. However, using second 
generation antigens and tests, seropositivity rates in healthy HCMV infected 
individuals have been suggested to be in the range of 90% (A. Wiegers, M. Mach, 
unpublished results) and the data presented here support this. 
It is also important to reiterate that OD values that are in the range of background 
are not necessarily indicative that a serum lacks antibodies to these epitopes. First, 
genuine epitope-specific antibodies could be potentially present at very low levels 
not detectable by ELISA.  Therefore a significant boost of these antibodies after just 
one vaccine dose could be explained by the existence of a memory B cell response 
specific to these epitopes. Alternatively, we cannot rule out the presence of some 
antibodies that react to the epitope in the context of native gB but fail to react in the 
ELISA because the epitope is not in its fully native context when presented as a 
partial subdomain of gB. 
Finally, although the data suggest AD2 levels are an important correlate of protection 
we do not rule out the possibility that responses against other, potentially novel, 
epitopes may also contribute. Attempts to perform a multi-variable analysis to test 
this were not possible due to the limited number of patients in the study (as the 
number of variables increases so does the requirement for more patients). Thus 
future phase II studies may need to be powered to ensure sufficient patients are 
recruited to allow more complex multivariate analyses. Future studies should also 
ensure the repeated sampling of the patients about to be challenged with the virus at 
the time of transplantation, the use of a randomised study design and incorporation 
of placebo controls – all aspects we consider significant strengths of our study. 
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Overall, the results described in this work build upon previous reports and support 
the concept that vaccination should be studied as a way of controlling HCMV 
replication. Although this analysis gives us more insight into the protective nature of 
humoral responses elicited by vaccination in seropositive SOT patients, many 
questions remain unanswered and follow up phase II studies with larger numbers of 
subjects recruited would add weight to all our observations. Additional antibody 
mediated effects may be important for the protection observed (e.g. complement 
mediated cell lysis and NK cell mediated ADCC) and this is the subject of ongoing 
investigation in the quest to provide protection against this important human 
pathogen. 
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Materials and methods: 
Antigens:  
The following gB-specific antigens, derived from HCMV strain AD169, were used: 
AD1 containing aa 484-650, was expressed in E.coli with galactosidase as a fusion 
partner. The construction of galactosidase containing plasmids has been described 
in detail elsewhere [30].  
AD2- short linear peptide containing aa 68-80, was synthetized chemically, as 
described in detail elsewhere [30, 33]. 
AD4 contained a fused polypeptide of aa 121-132 and 344-438. For determination of 
AD4-specific antibodies a purified GST-AD-4 fusion protein was used as antigen and 
expressed in E.coli, as described by Spindler et al [50]. 
AD5 containing aa 133 to 343. AD5-specific antibodies were determined in a capture 
ELISA using a mammalian cell (HEK 293T) derived AD5 polypeptide containing a 
HA-epitope tag at the amino terminus of the protein as described elsewhere [49]. To 
capture the antigen, an anti-HA monoclonal antibody (clone HA-7, Sigma-Aldrich) 
was diluted to 1 µg/ml in 0.05 M sodium carbonate buffer; pH 9.6, and 50 µl/well was 
used to coat polystyrene 96-well plates (NuncImmuno™) overnight at 4°C.  
ELISA:  
All reactions were performed at 37°C. Reaction wells were rinsed with PBS 
supplemented with 0.1% Tween then the reaction wells were blocked with PBS 
containing 2% fetal calf serum for 1 h, washed three times with phosphate buffered 
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saline (PBS) plus 0.1% Tween 20 and incubated with antigens for 2 h. The plate was 
washed three times with PBS containing 0.1% Tween 20 and human serum was 
added at a dilution of 1:100 for 1 h. Dilution of all sera was done in PBS with 2% 
FCS. Unbound antibody was removed by washing three times and peroxidase-
conjugated secondary antibody (goat-anti-human IgG, Dianova) was added for 1 h. 
After three washing steps with 100 µl of tetramethylbenzidine peroxidase substrate 
was added for 3.5 min, diluted 1:1 in peroxidase substrate solution B (KPL, USA). 
The reaction was stopped by adding 100 µl of 1 M phosphoric acid. The optical 
density at 450 nm (OD450) was determined using an Emax microplate reader 
(Eurofins MWG Operon, Germany).  
Cut-off value was calculated based on the OD value in ELISA results with sera from 
seronegative patients (n=20). The highest OD value with seronegative sera was 
taken as a cut off for the experiment background and non-specific reactions in ELISA 
tests with seropositive patients.  
Patient population: 
The population investigated in this work is a subset of the original vaccine cohort 
(CMV seropositive pre-vaccination) from a group of SOT patients (NCT00299260) 
enrolled in a phase-2 randomised and double-blinded placebo-controlled 
cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant trial [25]. All prospective 
transplant patients are serotyped as part of NHS standard procedure using an 
antibody based ELISA. The vaccine or placebo was given in three doses: at day 0 
(baseline), 1 month and 6 months later. Blood samples were collected at day 0- at 
the time of vaccination (visit 1), at the time of the administration of the second dose, 
one month following the administration of the first dose (visit 2), at 2 months 
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following the administration of the 1st dose (visit 3), at the time of the administration 
of the 3rd dose, 6 months following the administration of the first dose (visit 4) and at 
7 months following the administration of the first dose of vaccine (visit 5). Exclusion 
criteria included: pregnancy (a negative pregnancy test was required before each 
vaccine dose); receipt of blood products (except albumin) in the previous 3 months, 
and simultaneous multi-organ transplantation [25].  
Samples: 
Blood samples (5ml) were collected in sterile tubes (without anticoagulant) and then 
left in a standing position for approximately half an hour to allow blood to clot. The 
samples were centrifuged at RT at 1500g for 15min and the serum fraction 
separated from the clot. Serum samples were stored at -78°C prior to analysis. 
Statistical analyses: 
The analysis of the results was performed by Graph Pad Prism®-software. Statistical 
differences between the mean value of the OD of the samples obtained at the same 
time points in the same experimental run between populations of patients: 
vaccinated vs placebo and viremia vs no viremia were obtained from Mann Whitney 
Test (ns: not significant; *: P < 0.05; **: P < 0.005; ***: P < 0.005). Geometric mean 
values (±95%CI) were represented by horizontal lines.   
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Fig. 1. The majority of seropositive patients have pre-existing AD1 immune 
responses boosted by vaccination.  
AD1 responses are represented as OD values at different time-points: day of first 
vaccine/placebo administration (month 0); day of administration of the second 
(month 1) and third dose (month 6), and 2 and 7 months post vaccination. (A) AD1 
responses in HCMV seropositive vaccine recipients represented as OD values (B) 
AD1 responses in HCMV seropositive placebo recipients represented as OD values 
(C) Comparison between antibody levels against AD1 in the sera from vaccinated 
and placebo patients. Horizontal lines represent geometric mean values (±95%CI). 
Statistical differences between the mean value of ODs between the populations of 
patients: vaccinated vs placebo were obtained from Mann Whitney Test (ns: not 
significant; *: P < 0.05; **: P < 0.005; ***: P < 0.005). 
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Fig 2. The majority of seropositive patients have pre-existing AD4 immune 
responses boosted by vaccination.  
AD4 responses are represented as OD values at different time-points: day of first 
vaccine/placebo administration (month 0); day of administration of the second 
(month 1) and third dose (month 6), and 2 and 7 months post vaccination. (A) AD4 
responses in HCMV seropositive vaccine recipients represented as OD values (B) 
AD4 responses in HCMV seropositive placebo recipients represented as OD values 
(C) Comparison between antibody levels against AD4 in the sera from vaccinated 
and placebo patients. Horizontal lines represent geometric mean values (±95%CI). 
Statistical differences between the mean value of ODs between the populations of 
patients: vaccinated vs placebo were obtained from Mann Whitney Test (ns: not 
significant).
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Fig 3. Vaccination boosts pre-existing AD5 responses and induces detectable 
de novo responses in patients. 
AD5 responses are represented as OD values at different time-points: day of first 
vaccine/placebo administration (month 0); day of administration of the second 
(month 1) and third dose (month 6), and 2 and 7 months post vaccination. (A) AD5 
responses in HCMV seropositive vaccine recipients represented as OD values (B) 
AD5 responses in HCMV seropositive placebo recipients represented as OD values 
(C) Comparison between antibody levels against AD5 in the sera from vaccinated 
and placebo patients. Horizontal lines represent geometric mean values (±95%CI). 
Statistical differences between the mean value of ODs between the populations of 
patients: vaccinated vs placebo were obtained from Mann Whitney Test (ns: not 
significant).*: P < 0.05). 
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Fig 4. Vaccination does not induce detectable de novo responses in patients 
lacking pre-existing AD2 responses but boosts pre-existing antibody 
responses above cut-off against AD2 in HCMV seropositive patients. 
AD2 responses are represented as OD values at different time-points: day of first 
vaccine/placebo administration (month 0); day of administration of the second 
(month 1) and third dose (month 6), and 2 and 7 months post vaccination. (A) AD2 
responses in HCMV seropositive vaccine recipients represented as OD values (B) 
AD2 responses in HCMV seropositive placebo recipients represented as OD values 
(C) Comparison between antibody levels against AD2 in the sera from vaccinated 
and placebo patients. (D) Comparison between antibody levels against AD2 
responses in patients who had pre-existing antibody responses. AD2 responses are 
represented as OD values at day of first vaccine/placebo administration (pre-
vaccination) and 2 months following the administration of the first dose of the vaccine 
(post-vaccination). The dotted line represents a cut-off value (the highest OD value 
in seronegative group at the time of vaccine administration).Horizontal lines 
represent geometric mean values (±95%CI). Statistical differences between the 
mean value of ODs between the populations of patients: vaccinated vs placebo were 
obtained from Mann Whitney Test (ns: not significant; *: P < 0.05). 
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Figure 5. Elevated antibody responses against AD2 correlate with protection. 
Comparison of antibody levels against AD1 (A), AD2 (B), AD4 (C) and AD5 (D) 
between patients who developed viremia versus patients who did not develop 
viremia following transplantation at day of first vaccine/placebo administration (month 
0); day of administration of the second (month 1) and third dose (month 6), and also 
at times: 2 and 7 months post initial vaccination. Horizontal lines represent geometric 
mean values. Statistical differences between the mean value of ODs between the 
populations of patients: viremia vs no viremia were obtained from Mann Whitney 
Test (ns: not significant; *: P < 0.05). 
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Figure 6. No evidence for antagonistic antibody responses between AD1 and 
AD2 affecting outcome. 
A) Hypothetical models of interactions between AD1 and AD2 antibody responses 
and clinical outcome. B) AD2 (Y axis) and AD1 (X axis), represented as OD values 
at 2 months following the administration of the 1st dose of vaccine. Red colour 
represent patients who subsequently developed viremia post-transplant and black 
colour represent patients who did not experience viremia post-transplant. 
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Table 1. Summary of antibody responses in sera from HCMV seropositive 
patients vaccinated with the subunit glycoprotein-B vaccine with MF-59 
adjuvant against four key antigenic domains mapped onto gB. 
Protection from viremia is defined when patient did not experience an episode of 
viremia during the course of analyses (viremia>200 cps/ml). 
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Antigenic 
domain 
HCMV seropositive vaccine recipients 
Induction of 
antibody 
responses 
de novo 
Boost of 
pre-existing 
responses 
% positivity 
prior to 
vaccination 
% 
positivity 
following 
vaccination 
protection 
from 
viremia 
AD1 Yes (fig. 1) Yes (fig.1) 
86.4% 
(38/44) 
93.8% 
(15/16) 
No 
AD2 No (fig.4 & 5) 
Yes (fig.4 & 
5) 
50% (23/46) 50% (9/18) Yes 
AD4 No (fig. 2) Yes (fig. 2) 98% (43/44) 
93.8% 
(15/16) 
Trend 
AD5 Yes (fig. 3) Yes (fig. 3) 97.7 (43/44) 95.8 (23/24) No 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy102/4924673
by Periodicals Section , London Metropolitan University user
on 12 March 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Figure 1. 
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Figure 2. 
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Figure 4. 
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Figure 6. 
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